Cell-based drugs developer Promethera Biosciences has closed a Series D financing round to support its expansion in Asian markets, along with the development of liver disease programmes.
Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of a €10 million investment from Japanese business conglomerate ITOCHU Corporation.